Blackstone’s Earnings In Focus: BofA Analyst Estimates In-Line But Sees Improving Outlook
BofA Securities analyst expects bullish outlook for Blackstone's Q4 FY23 earnings, notes growth potential in retail and insurance businesses.
Why Energy Equipment & Services Firm Halliburton Shares Are Higher Today
Halliburton reported mixed fourth quarter results. The company raised its 2024 first quarter dividend by $0.01 to $0.17 per share. The company said its outlook for oilfield services demand remains strong.
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Why Truck Manufacturer PACCAR Shares Are Up Today
PACCAR reported strong Q4 FY23 sales of $8.59B, exceeding analyst expectations. Globally, the company delivered a record of 204,200 vehicles in the year.
Lockheed Martin Expects ‘Topline Growth’ After Q4 Earnings Marginally Surpass Estimates
Lockheed Martin's robust fourth-quarter 2023 performance CEO Jim Taiclet anticipates continued growth in 2024.
Johnson & Johnson’s Clock 12% Q4 Revenue Growth, Cancer and Crohn’s Disease Drugs Account as Largest Sellers
Johnson & Johnson's Q4 2023 performance, with adjusted earnings up 11.7%, sales at $21.4 billion, and key insights into pharmaceutical and MedTech segments.
Netflix Enters The Ring: Clinches $5B WWE Deal, Adds Live Wrestling To Streaming Lineup
Netflix secures exclusive rights to WWE's 'Raw' and other shows for 10 years starting Jan 2025, expanding its reach and venturing into live events.
Brown & Brown Takes Off: Q4 Results Send Stock Higher As Company Sets $8B Revenue Goal
Brown & Brown Inc (BRO) reports Q4 2023 results with $1.03B revenue (+13.8% Y/Y), aligns business into 3 segments, declares $0.13 dividend.
Lockheed Martin Vs. Raytheon Technologies: Which Is The Better Buy Post Q4 Earnings?
Both Lockheed Martin and its rival, Raytheon Technologies, have demonstrated solid revenue growth. One of them offers a better upside.
Bristol Myers Squibb’s Combo Therapy Shows Sustained Benefits Over Pfizer’s Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight years.